TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00662324

Intervention type: BEHAVIORAL
Intervention: focus groups
Description: Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes.

Intervention type: BEHAVIORAL
Intervention: focus groups
Description: Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes.

Intervention type: BEHAVIORAL
Intervention: focus groups
Description: MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes.
Study: NCT02881086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Study: NCT03031262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
Study: NCT02881086

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell transplantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Study: NCT03031262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide at a dose of 20mg/d twice a week for 3 months.
Study: NCT00502372

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Supplement/Amino acids and HMB
Description: Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement/Amino acids and HMB
Description: Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
Study: NCT02881086

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine

Intervention type: DRUG
Group type: OTHER
Intervention: Vindesine

Intervention type: DRUG
Group type: OTHER
Intervention: Vindesine

Intervention type: DRUG
Group type: OTHER
Intervention: Vindesine

Intervention type: DRUG
Group type: OTHER
Intervention: Vindesine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin

Intervention type: DRUG
Group type: OTHER
Intervention: Adriamycin

Intervention type: DRUG
Group type: OTHER
Intervention: Adriamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Study: NCT00298740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aventis U-400 Insulin
Study: NCT03235609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl used with propofol for sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine used with propofol for sedation
Study: NCT03439579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home weight loss program
Description: Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
Study: NCT01526460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 80 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no statin loading dose
Study: NCT03519282

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A multifocal toric lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A multifocal toric lens
Description: contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A Multifocal Toric Lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A Multifocal Toric Lens
Description: contact lens
Study: NCT00502372

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Juven
Description: comparison of Juven with arginine only product in wound healing

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Description: comparison of Juven with arginine only product in wound healing
Study: NCT03590288

Intervention type: PROCEDURE
Intervention: Transjugular intrahepatic portosystemic shunt
Description: Covered stents will be used, that will be dilated to 8 mm. The aim will be to reduce the portacaval pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of portacaval pressure gradient will be done immediate after TIPS, then repeated 1-3 days and at 1 month after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected.
Study: NCT03015454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Sepsis Prediction
Description: Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study: NCT00672776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04339738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02305186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant Chemoradiation
Description: Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
Study: NCT03968497

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative pain assessment with female investigator
Description: Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
Study: NCT02305186

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiation
Description: Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
Study: NCT02604511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study: NCT00267930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Study: NCT03015454

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Severe Sepsis Detection
Description: Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Severe Sepsis Detection
Description: Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
Study: NCT01350960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC5001
Description: 3 weekly SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPC5001
Description: 3 weekly SC injections
Study: NCT02964429

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diacap Pro High-Flux
Description: During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
Study: NCT01231113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate-amodiaquine
Description: The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Description: a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
Study: NCT03368378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early DVC ligation
Description: After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early DVC ligation
Description: After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
Study: NCT02562352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAPER program
Description: Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
Study: NCT02507336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100-300 mg capsule taken by mouth once daily.
Study: NCT06156111

Intervention type: DEVICE
Group type: OTHER
Intervention: Transepithelial abutment group
Description: Before completing the essential clinical data registration to produce an individual patient-oriented prosthesis, trans-epithelial abutments on the implants randomized to this group will be put at the torque the manufacturer recommends (30 Ncm typically), according to the appropriate gingival height and then the fixed implant-supported monolithic zirconia will be placed at the torque of 15 Ncm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Direct to implant group
Description: It will be registered the essential clinical data registration to produce an individual patient-oriented prosthesis, and then the fixed implant-supported monolithic zirconia will be placed at the torque of 30 Ncm.
Study: NCT02528097

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: 25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr \> 1.0 or BUN or Cr \> baseline)
Study: NCT00536978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARA-C
Description: 100 mg/m\^2 IV Daily Over 1 Hour for 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300 mg/m\^2 IV Over 1 Hour for 1 Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 15 mg IV Daily Over 30 Minutes for 3 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m\^2 IV Daily Over 3 Hours for 4 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 IV Daily Over 1 Hour for 3 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 100 mg/m\^2 IV Over 30 Minutes for 1 Day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m\^2 IV Over 5-7 Hours Weekly for 3 Weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Stem Cell Infusion on Day 0.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body radiation (TBI)
Description: TBI on Day 5 following chemotherapy, before stem cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 IV on Days +1, +3, and +6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adback NK or T Cell
Description: Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
Study: NCT05931523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress First Aid
Description: The focus of the model is ongoing monitoring of stress in personnel, wide spread training to help personnel recognize peers or subordinates who may need additional assistance, a spectrum of one-on-one interventions, and the ability to provide personnel higher levels of care when indicated.
Study: NCT01085305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy
Description: Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
Study: NCT03968497

Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative pain assessment with male investigator
Description: Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
Study: NCT01085305

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: Usual treatment for behavioral disorders
Study: NCT04031092

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable tech with feedback
Description: An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable tech without feedback
Description: An armwrist device measuring physical activity level, no reporting back to the user.
Study: NCT01907243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spreader flap
Description: producing of upper lateral cartilage flap as a spreader flap
Study: NCT02241252

Intervention type: DEVICE
Group type: OTHER
Intervention: iPhone ECG
Description: Please see detailed description for additional information.
Study: NCT03004742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavonoid
Description: Flavonoid rich supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01033058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
Study: NCT02445508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystokinin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecystokinin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevelamer placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Study: NCT03119233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PQ Bypass System
Description: Intended use from CLN114 Rev F (CLN114 is the DETOUR2 protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm (TASC D) that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis (complex TASC C).
Study: NCT04152473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proglumide
Description: oral CCK receptor antagonist
Study: NCT04420442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scar Transformation Group
Description: Surgical excision of the NSSI scars followed by IntegraTM transplantation and wound closure with a negative pressure wound system. After 21 days the silicone layer of the IntegraTM will be removed and split thickness skin will be transplanted. After suture removal a compression therapy by individually tailored garments will be started for 12 months.
Study: NCT03397537

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole 2.5Mg Tablet
Description: letrozole 2.5mg p.o.qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5Mg Tablet
Description: letrozole 2.5mg p.o.qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH analogue
Description: 3.75 mg triptorelin im. q28d